Altre lingue Cynata Therapeutics Limited

Azioni

CYP

AU000000CYP7

Mercato chiuso - Australian S.E. Altri mercati azionari 07:58:24 02/05/2024			Variaz. 5gg	Var. 1 gen.
0,235 ^AUD	+4,44%		+17,50%	+88,00%

08/04	Cynata Therapeutics Limited completa l'arruolamento dei pazienti nello studio clinico CYP-006TK sull'ulcera del piede diabetico	CI
08/04	Cynata Therapeutics conclude l'arruolamento dei pazienti nello studio del prodotto per la medicazione delle ulcere del piede diabetico	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Cynata Therapeutics Limited Completes Patient Enrolment in CYP-006TK Diabetic Foot Ulcer Clinical Trial	08/04
Cynata Therapeutics Concludes Patient Enrolment in Diabetic Foot Ulcer Wound Dressing Product Trial	08/04
Cynata Therapeutics Receives EU Approval for CYP-001 Phase 2 Trial	20/03
Cynata Therapeutics Doses First Patient in Phase Two Trial of Cellular Therapy; Shares Rise 5%	05/03
Cynata Therapeutics Limited Announces Updates on Phase 2 Clinical Trial of CYP-001	05/03
Cynata Therapeutics Names Chief Business Officer; Shares Plunge 14%	29/02
Cynata Therapeutics Limited Announces Initial Data from CYP-006TK Diabetic Foot Ulcer Clinical Trial	26/02
Cynata Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	23/02
Cynata Therapeutics Expects Initial Results in Diabetic Foot Ulcer Topical Wound Dressing Trial in Q1 2024	28/12
Cynata Therapeutics Completes Recruitment for Phase Three Osteoarthritis Trial	13/12
Cynata Therapeutics Secures Approval in Turkey for Phase 2 Trial of HR-aGvHD; Shares Jump 9%	07/12
Cynata Therapeutics Receives AU$2.3 Million R&D Tax Rebate	14/11
Acute Respiratory Distress Syndrome Pipeline \| Clinical Trials and Key Companies	08/11
Cynata Therapeutics Secures Clearance to Advance Phase Three Knee Pain Trial	06/11
Cynata Therapeutics Limited Announces Resignation of David Atkins as Director	08/10/23
Cynata Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2023	28/08/23
Cynata Therapeutics Opens Enrollment for Phase Two Cell Therapy Trial	10/08/23
Cynata Therapeutics Taps COO for CEO/Managing Director Role; Shares Down 4%	30/06/23
Cynata Therapeutics Limited Announces Management Appointments	30/06/23
Cynata Therapeutics Limited Announces Chief Executive Officer Changes	30/06/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Cynata Therapeutics Limited

Azioni

CYP

AU000000CYP7

Altre lingue

Filtri